ESPR (Esperion Therapeutics) Total Inventories : $94.5 Mil (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics Total Inventories?

Esperion Therapeutics's total inventories for the quarter that ended in Dec. 2024 was $94.5 Mil. Esperion Therapeutics's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $87.3 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Esperion Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-2.45.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Esperion Therapeutics's Days Inventory for the three months ended in Dec. 2024 was 310.79.

Inventory Turnover measures how fast the company turns over its inventory within a year. Esperion Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 was 0.29.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Esperion Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 1.26.

Esperion Therapeutics Total Inventories Historical Data

The historical data trend for Esperion Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Total Inventories Chart

Esperion Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

16.14

34.39

35.20

65.62

94.49

Esperion Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															65.62	73.10	84.47	80.10	94.49

Esperion Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Esperion Therapeutics (NAS:ESPR) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Esperion Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

	Net-Net Working Capital Per Share (Q: Dec. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(144.761	+	0.75 * 80.142	+	0.5 * 94.491	-	732.543
-	0	-	0)	/	195.852
=	-2.45

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Esperion Therapeutics's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	87.2965	/	25.631	*	365 / 4
	=	310.79

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Esperion Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	25.631	/	87.2965
	=	0.29

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Esperion Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	87.2965	/	69.113
	=	1.26

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Esperion Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

0IIM:UK 0ET:Germany 0ET:Germany

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Executives

Benjamin Halladay	officer: Chief Financial Officer	ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Sheldon L. Koenig	officer: Chief Operating Officer	C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Eric Warren	officer: Chief Commercial Officer	3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joanne M. Foody	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll	director	C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli	director	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Benjamin Looker	officer: General Counsel	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director, officer: Pres & Chief Executive Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall	officer: Chief Development Officer	C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram	officer: Chief Financial Officer	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo	director, 10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121